VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 127 filers reported holding VAXCYTE INC in Q3 2022. The put-call ratio across all filers is 0.98 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,827,527 | +78.3% | 75,079 | +74.7% | 0.00% | +100.0% |
| Q2 2023 | $2,146,422 | +15.6% | 42,980 | -13.2% | 0.00% | 0.0% |
| Q1 2023 | $1,856,347 | +9.1% | 49,529 | +39.5% | 0.00% | 0.0% |
| Q4 2022 | $1,701,986 | +197.6% | 35,495 | +49.0% | 0.00% | – |
| Q3 2022 | $572,000 | -0.7% | 23,827 | -10.1% | 0.00% | – |
| Q2 2022 | $576,000 | -1.9% | 26,491 | +9.1% | 0.00% | – |
| Q1 2022 | $587,000 | -17.8% | 24,286 | -19.2% | 0.00% | – |
| Q4 2021 | $714,000 | -1.8% | 30,044 | +4.8% | 0.00% | – |
| Q3 2021 | $727,000 | +8.8% | 28,676 | -3.5% | 0.00% | – |
| Q2 2021 | $668,000 | +76.7% | 29,705 | +55.0% | 0.00% | – |
| Q1 2021 | $378,000 | +3.3% | 19,160 | +39.0% | 0.00% | – |
| Q4 2020 | $366,000 | -23.9% | 13,782 | +41.5% | 0.00% | – |
| Q3 2020 | $481,000 | – | 9,737 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 1,457,300 | $54,619,604 | 23.40% |
| Pivotal bioVenture Partners Investment Advisor LLC | 693,039 | $25,975,102 | 10.70% |
| RA Capital Management | 7,291,254 | $273,276,200 | 6.19% |
| Kynam Capital Management, LP | 1,216,784 | $45,605,064 | 5.89% |
| GREAT POINT PARTNERS LLC | 659,211 | $24,707,228 | 4.85% |
| Frazier Life Sciences Management, L.P. | 1,397,405 | $52,374,739 | 3.79% |
| ACUTA CAPITAL PARTNERS, LLC | 120,500 | $4,516,340 | 3.33% |
| Ghost Tree Capital, LLC | 225,000 | $8,433,000 | 2.49% |
| Carlyle Group Inc. | 1,923,158 | $72,079,962 | 2.15% |
| Opaleye Management Inc. | 177,000 | $6,633,960 | 1.99% |